The gut–immune axis during hypertension and cardiovascular diseases
Acta Physiologica · 2024-08 · 240 (8)
DOI: 10.1111/apha.14193 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Physiologica, online erschienen am 20.06.2024. Verfasst von Evany Dinakis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hypertension Research Laboratory, School of Biological Sciences, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Hypertension, Cardiovascular Diseases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Health and Medical Research Council, Sylvia and Charles Viertel Charitable Foundation.
Abstract (Originalsprache)
The gut‐immune axis is a relatively novel phenomenon that provides mechanistic links between the gut microbiome and the immune system. A growing body of evidence supports it is key in how the gut microbiome contributes to several diseases, including hypertension and cardiovascular diseases (CVDs). Evidence over the past decade supports a causal link of the gut microbiome in hypertension and its complications, including myocardial infarction, atherosclerosis, heart failure, and stroke. Perturbations in gut homeostasis such as dysbiosis (i.e., alterations in gut microbial composition) may trigger immune responses that lead to chronic low‐grade inflammation and, ultimately, the development and progression of these conditions. This is unsurprising, as the gut harbors one of the largest numbers of immune cells in the body, yet is a phenomenon not entirely understood in the context of cardiometabolic disorders. In this review, we discuss the role of the gut microbiome, the immune system, and inflammation in the context of hypertension and CVD, and consolidate current evidence of this complex interplay, whilst highlighting gaps in the literature. We focus on diet as one of the major modulators of the gut microbiota, and explain key microbial‐derived metabolites (e.g., short‐chain fatty acids, trimethylamine N ‐oxide) as potential mediators of the communication between the gut and peripheral organs such as the heart, arteries, kidneys, and the brain via the immune system. Finally, we explore the dual role of both the gut microbiome and the immune system, and how they work together to not only contribute, but also mitigate hypertension and CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hypertension Research Laboratory, School of Biological Sciences, Monash University, Melbourne, Victoria, Australia.
- Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Francine Z Marques
Förderung
- Wellcome Trust
- National Health and Medical Research Council
- Sylvia and Charles Viertel Charitable Foundation
- National Heart Foundation of Australia
Zitieren
APA
Dinakis, E., O'Donnell, J. A., & Marques, F. Z. (2024). The gut–immune axis during hypertension and cardiovascular diseases. Acta Physiologica, 240(8). https://doi.org/10.1111/apha.14193
Vancouver
Dinakis E, O'Donnell JA, Marques FZ. The gut–immune axis during hypertension and cardiovascular diseases. Acta Physiologica. 2024;240(8). doi:10.1111/apha.14193
BibTeX
@article{Dinakis2024,
author = {Dinakis, Evany and O'Donnell, Joanne A and Marques, Francine Z},
title = {The gut–immune axis during hypertension and cardiovascular diseases},
journal = {Acta Physiologica},
year = {2024},
volume = {240},
number = {8},
doi = {10.1111/apha.14193}
}
EUVIMED